Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ado-trastuzumab Emtansine (T-DM1) in HER2-positive Salivary Gland Carcinomas
NCT04620187Phase 2Recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Dec 2020
- Primary completion
- Feb 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab emtansine in salivary gland carcinoma (SGC), sponsored by Dana-Farber Cancer Institute. Started Dec 2020; status: recruiting.
02
Drugs
trastuzumab emtansine
03
Conditions
salivary gland carcinoma (SGC)
Beyond the preview
Go deeper on NCT04620187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04620187.